Literature DB >> 19294006

Immunohistochemical detection of estrogen and progesterone receptor and HER2 expression in breast carcinomas: comparison of cell block and tissue block preparations.

Sharenda L Williams1, George G Birdsong, Cynthia Cohen, Momin T Siddiqui.   

Abstract

Fine needle aspiration (FNA) is a rapid tool for detection of breast carcinomas. Evaluation of estrogen and progesterone receptors (ER, PR) and HER2 expression by immunohistochemistry (IHC) are routinely performed in breast carcinomas. Formalin fixation of tissue for a minimum of 6 hours, and for HER2 not more than 48 hours is the current recommended practice. In this retrospective study, we compared ER, PR and HER2 expression in breast carcinomas using archival ethanol-fixed FNA cell block with formalin fixed resection tissue block preparations. 34 archival breast carcinoma FNA cell blocks of primary origin with subsequent resection tissue blocks were identified retrospectively. All 34 cases were diagnosed as invasive ductal carcinoma. Cases with neoadjuvant or adjuvant chemotherapy were excluded. Cell blocks were initially fixed in 50% ethanol (4-12 hrs), followed by formalin fixation (minimum 6 hrs). Tissue blocks were formalin-fixed within 4-8 hrs for 6-48 hrs. ER, PR, and HER2 IHC results on the cell blocks and tissue blocks were compared. Alcohol fixed cell block samples for detection of ER and PR by IHC show good agreement with tissue block samples and are therefore a reliable method (weighted Kappa of 0.773 and 0.785, respectively) to triage patients for hormonal treatment. However, HER2 results show only moderate agreement with a weighted kappa of 0.571. The increase in discrepant results may be due to ethanol fixation which results in false positive increased HER2 expression. These results demonstrate the importance of adherence to the College of American Pathologists/ASCO guidelines for HER2 IHC.

Entities:  

Keywords:  ER; HER2; PR; alcohol fixation; breast carcinoma; cell block; fine needle aspiration; formalin fixation; immunohistochemistry

Year:  2009        PMID: 19294006      PMCID: PMC2655151     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  18 in total

1.  National HER2 proficiency test results using standardized quantitative controls: characterization of laboratory failures.

Authors:  Kodela Vani; Seshi R Sompuram; Patrick Fitzgibbons; Steven A Bogen
Journal:  Arch Pathol Lab Med       Date:  2008-02       Impact factor: 5.534

2.  Optimization of immunohistochemical techniques to detect extracellular matrix proteins in fixed skin specimens.

Authors:  J M Folkvord; D Viders; A Coleman-Smith; R A Clark
Journal:  J Histochem Cytochem       Date:  1989-01       Impact factor: 2.479

Review 3.  Formaldehyde fixation.

Authors:  C H Fox; F B Johnson; J Whiting; P P Roller
Journal:  J Histochem Cytochem       Date:  1985-08       Impact factor: 2.479

4.  Laboratory testing for HER2/neu in breast carcinoma: an evolving strategy to predict response to targeted therapy.

Authors:  N M Diaz
Journal:  Cancer Control       Date:  2001 Sep-Oct       Impact factor: 3.302

5.  Interlaboratory comparison of immunohistochemical testing for HER2: results of the 2004 and 2005 College of American Pathologists HER2 Immunohistochemistry Tissue Microarray Survey.

Authors:  Patrick L Fitzgibbons; Douglas A Murphy; David M Dorfman; Patrick C Roche; Raymond R Tubbs
Journal:  Arch Pathol Lab Med       Date:  2006-10       Impact factor: 5.534

6.  Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma.

Authors:  Neal S Goldstein; Monica Ferkowicz; Eva Odish; Anju Mani; Farnaz Hastah
Journal:  Am J Clin Pathol       Date:  2003-07       Impact factor: 2.493

7.  The use of cell line standards to reduce HER-2/neu assay variation in multiple European cancer centers and the potential of automated image analysis to provide for more accurate cut points for predicting clinical response to trastuzumab.

Authors:  Anthony Rhodes; Duncan Borthwick; Rob Sykes; Salam Al-Sam; Angelo Paradiso
Journal:  Am J Clin Pathol       Date:  2004-07       Impact factor: 2.493

8.  Accuracy and precision in HER2/neu testing in breast cancer: are we there yet?

Authors:  Hadi Yaziji; Allen M Gown
Journal:  Hum Pathol       Date:  2004-02       Impact factor: 3.466

Review 9.  Current issues in ER and HER2 testing by IHC in breast cancer.

Authors:  Allen M Gown
Journal:  Mod Pathol       Date:  2008-05       Impact factor: 7.842

10.  Preservation of biomolecules in breast cancer tissue by a formalin-free histology system.

Authors:  Mehdi Nassiri; Sharon Ramos; Hajir Zohourian; Vladimir Vincek; Azorides R Morales; Mehrdad Nadji
Journal:  BMC Clin Pathol       Date:  2008-01-29
View more
  14 in total

1.  Comparative Proteome Analysis of Breast Cancer Tissues Highlights the Importance of Glycerol-3-phosphate Dehydrogenase 1 and Monoacylglycerol Lipase in Breast Cancer Metabolism.

Authors:  Kubra Karaosmanoglu Yoneten; Murat Kasap; Gurler Akpinar; Abdullah Gunes; Bora Gurel; Nihat Zafer Utkan
Journal:  Cancer Genomics Proteomics       Date:  2019 Sep-Oct       Impact factor: 4.069

2.  Impact of modern personalized treatment of breast cancer on surgical attitude and outcomes.

Authors:  Ciprian Tănăsescu; Dragos Serban; Andrei Moisin; Carmen Popa; Ramona Coca; George Iancu; Mihail Silviu Tudosie; Daniel Ovidiu Costea; Bogdan Socea; Corneliu Tudor; Gabriel Andrei Gangura; Laura Carina Tribus; Gabriel Catalin Smarandache
Journal:  Exp Ther Med       Date:  2021-11-17       Impact factor: 2.447

3.  Pathological Diagnosis, Work-Up and Reporting of Breast Cancer 1st Central-Eastern European Professional Consensus Statement on Breast Cancer.

Authors:  Gábor Cserni; Monika Francz; Balázs Járay; Endre Kálmán; Ilona Kovács; Tibor Krenács; Erika Tóth; Nóra Udvarhelyi; László Vass; András Vörös; Ana Krivokuca; Karol Kajo; Katarína Kajová Macháleková; Janina Kulka
Journal:  Pathol Oncol Res       Date:  2022-06-27       Impact factor: 2.874

4.  Preservation of immunorecognition by transferring cells from 10% neutral buffered formalin to 70% ethanol.

Authors:  D Otali; Q He; C R Stockard; W E Grizzle
Journal:  Biotech Histochem       Date:  2013-01-23       Impact factor: 1.718

5.  Testing for her2 in breast cancer: current pathology challenges faced in Canada.

Authors:  W Hanna; P Barnes; R Berendt; M Chang; A Magliocco; A M Mulligan; H Rees; N Miller; L Elavathil; B Gilks; N Pettigrew; D Pilavdzic; S Sengupta
Journal:  Curr Oncol       Date:  2012-12       Impact factor: 3.677

6.  Wogonoside inhibits invasion and migration through suppressing TRAF2/4 expression in breast cancer.

Authors:  Yuyuan Yao; Kai Zhao; Zhou Yu; Haochuan Ren; Li Zhao; Zhiyu Li; Qinglong Guo; Na Lu
Journal:  J Exp Clin Cancer Res       Date:  2017-08-03

7.  Evaluating Estrogen Receptor Immunohistochemistry on Cell Blocks From Breast Cancer Patients in a Low-Resource Setting.

Authors:  Asteria H Kimambo; Edda A Vuhahula; Amos R Mwakigonja; Britt-Marie Ljung; Li Zhang; Katherine Van Loon; Dianna L Ng
Journal:  Arch Pathol Lab Med       Date:  2021-07-01       Impact factor: 5.686

8.  HER 2 immunohistochemistry for breast cancer cell blocks can be used in the same way as that used for histological specimens.

Authors:  Rieko Nishimura; Nami Okamoto; Masakazu Satou; Kenta Kojima; Shinichi Tanaka
Journal:  Diagn Cytopathol       Date:  2016-01-22       Impact factor: 1.582

9.  Bright-field HER2 dual in situ hybridization (DISH) assay on breast cancer cell blocks: a comparative study with histological sections.

Authors:  Rieko Nishimura; Nami Okamoto; Masakazu Satou; Kenta Kojima; Shinichi Tanaka; Natsumi Yamashita
Journal:  Breast Cancer       Date:  2016-01-08       Impact factor: 4.239

Review 10.  In vitro comparative models for canine and human breast cancers.

Authors:  Simona Visan; Ovidiu Balacescu; Ioana Berindan-Neagoe; Cornel Catoi
Journal:  Clujul Med       Date:  2016-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.